These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2005-003463-23 ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB 2016-10-15 bad-data
Exempt 2006-004770-27 TRAITEMENT NEOADJUVANT DU CANCER DE L’ŒSOPHAGE OPERABLE A VISEE CURATIVE PAR 5-FLUOROURACILE, CISPLATINE ET CETUXIMAB + RADIOTHERAPIE CONCOMITANTE. ÉTUDE DE PHASE I-II not-yet-due
Ongoing 2007-001772-37 Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des pat... not-yet-due
Ongoing 2008-005959-19 Etude de phase II non contrôlée: traitement de première ligne par sunitinib plus folfiri pour les patients ayant un cancer du rectum avec des métastases synchrones résécables (SUREMETS) not-yet-due
Ongoing 2008-007928-25 ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP... not-yet-due
Ongoing 2009-014443-36 Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d’efficacité du Torisel® (Temsirolimus) not-yet-due
Ongoing 2009-017064-16 Essai randomisé en double aveugle de phase II/III évaluant la chimioembolisation combinée au sunitinib ou à un placebo chez des patients atteints de carcinome hépatocellulaire (SATURNE) not-yet-due
Ongoing 2009-017996-11 ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP... not-yet-due
Not reported 2010-022987-11 PHARMACOGENETIQUE DE LA GEMCITABINE : ETUDE DE L’IMPACT DU POLYMORPHISME GENETIQUE DE LA CYTIDINE DEAMINASE (CDA) SUR LA TOXICITE ET L’EFFICACITE THERAPEUTIQUE DANS LES ADENOCARCINOMES PANCREATIQUES R... 2016-09-15 due-trials
Ongoing 2012-002224-32 Evérolimus comme traitement après embolisation ou chimioembolisation de métastases hépatiques de tumeur endocrine digestive not-yet-due
Ongoing 2013-004069-14 A european, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrine t... not-yet-due
Ongoing 2014-001837-10 PHASE II RANDOMIZED TRIAL EVALUATING AFLIBERCEPT ASSOCIATED WITH SCHEME LV5FU2 AS FIRST LINE TREATMENT OF NON-RESECTABLE METASTATIC COLORECTAL CANCERS not-yet-due
Ongoing 2014-002517-39 Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more not-yet-due
Ongoing 2015-002086-29 PHASE II STUDY EVALUATION OF EFFICACITY AND TOLERANCE OF REGORAFENIB FOR 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL ADENOCARCIMA not-yet-due
Ongoing 2016-004575-49 MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATE... not-yet-due
Ongoing 2017-001683-37 SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients not-yet-due
Ongoing 2017-004309-41 Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pa... not-yet-due